Median overall survival for GPS and Keytruda® combination was 18.4 Months compared to 13.8 Months in a Keytruda® single agent…
Neuropilin-1 (NRP1), implicated in various pro-tumorigenic processes, is a promising therapeutic target for cancer treatmentSecarna designed LNA-modified NRP1 specific antisense…
Potential to address cancer treatment related Cytokine Release SyndromeLONDON, UK / ACCESSWIRE / November 3, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF),…
Planegg/Martinsried, November 4, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the…
The first experimental agent from the enLIGHTEN™ Discovery Platform is Alpha-201-macro1, an investigational viral immunotherapy designed to activate innate immune…
Data further characterize the mechanism for Gamida Cell’s proprietary nicotinamide (NAM) technology’s expansion and enhancement of cellsBOSTON, Nov. 04, 2023…
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patientsWOBURN, Mass.,…
In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer…
— Data demonstrate preclinical potent T cell activation and differentiated mechanism of action and enhanced clinical efficacy irrespective of PD-L1…
First study of patients with metastatic prostate cancer to evaluate standard-of-care chemotherapy (docetaxel) combined with an antibody drug conjugate (PDS0301).Decrease…